Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis
- Resource Type
- Authors
- Rachel Glicksman; A.U. Kishan; David Shabsovich; Sean P. Collins; Constantine Mantz; Andrew Loblaw; Michael L. Steinberg; Donald B. Fuller; L. Zhang; Alan J. Katz
- Source
- Clinical oncology (Royal College of Radiologists (Great Britain)). 34(1)
- Subject
- Response rate (survey)
Oncology
Male
medicine.medical_specialty
business.industry
Prostatic Neoplasms
Prostate-Specific Antigen
medicine.disease
Radiosurgery
Confidence interval
Metastasis
Prostate cancer
Prostate-specific antigen
Interquartile range
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Cumulative incidence
Prospective Studies
Intermediate risk
business
Proportional Hazards Models
- Language
- ISSN
- 1433-2981
AIMS There is a lack of early predictive measures of outcome for patients with intermediate-risk prostate cancer (PCa) treated with stereotactic body radiotherapy (SBRT). The aim of the present study was to explore 4-year prostate-specific antigen response rate (4yPSARR) as an early predictive measure. MATERIALS AND METHODS Individual patient data from six institutions for patients with intermediate-risk PCa treated with SBRT between 2006 and 2016 with a 4-year (42-54 months) PSA available were analysed. Cumulative incidences of biochemical failure and metastasis were calculated using Nelson-Aalen estimates and overall survival was calculated using the Kaplan-Meier method. Biochemical failure-free survival was analysed according to 4yPSARR, with groups dichotomised based on PSA